Ignite Creation Date:
2024-05-06 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05730894
Status:
RECRUITING
Last Update Posted:
2023-02-16
First Post:
2022-12-05
Brief Title:
Predictors of Mortality in Patients With VA-Extracorporeal Membrane Oxygenation
Sponsor:
Hamad Medical Corporation
Organization:
Hamad Medical Corporation
Study Overview
Official Title:
Predictors of Mortality in Patients With VA-Extracorporeal Membrane Oxygenation A Retrospective Data Review
Status:
RECRUITING
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ECMO
Brief Summary:
Venoarterial extracorporeal membrane oxygenation VA-ECMO support is a lifesaving tool used to treat cardiogenic shock acute heart failure or extracorporeal cardiopulmonary resuscitationCPR However its use is associated with significant complications including mortality We aim to conduct a retrospective observational study of all patients at Heart Hospital who required VA-ECMO support due to cardiogenic shock during 1062016 and 1062022 to report the incidence of in-hospital mortality among patients who required VA-ECMO along with the predictors of mortality Data will be collected to identify baseline characteristics and outcomes including clinical variables predictive of poor outcomes
Detailed Description:
Extracorporeal membrane oxygenation ECMO is an advanced life support modality for critically ill patients with refractory cardiac or respiratory failure It is a temporary support for cardiorespiratory failure bridging time for recovery or permanent assist Besides ECMO could be used in a variety of clinical presentations such as severe traumas extracorporeal-assisted rewarming ECAR of accidental deep hypothermia and can be used as a bridge to lung or heart transplant
Cardiogenic shock can be a fatal condition with poor prognosis Conventional treatments for cardiogenic shock include vasopressor agents guided by invasive monitoring and intraaortic balloon pump support There has been growing interest in the use of veno-arterial extracorporeal membrane oxygenation VA-ECMO as a salvage therapy for patients in cardiogenic shock refractory to conventional treatments However there is a low rate of survival to weaning or bridging therapy among patients with cardiogenic shock requiring ECMO 42-56 Moreover VA-ECMO use is associated with complications including bleeding renal failure Thus the benefits of this potentially life-saving support is still subject to discussion especially for VA-ECMO use in the setting of cardiogenic shock as the evidence is scarce Therefore it important to identify the patients related factors that may be associated with poor outcomes using real-world data We will conduct a retrospective observational study of all patients at Heart Hospital who required VA-ECMO support due to cardiogenic shock during 1062016 and 1062022 with the aim of quantifying the incidence of in-hospital mortality among patients who required VA-ECMO in the setting of cardiogenic shock along with determining the predictors of mortality
Cardiogenic shock can be a fatal condition with poor prognosis Conventional treatments for cardiogenic shock include vasopressor agents guided by invasive monitoring and intraaortic balloon pump support There has been growing interest in the use of veno-arterial extracorporeal membrane oxygenation VA-ECMO as a salvage therapy for patients in cardiogenic shock refractory to conventional treatments However there is a low rate of survival to weaning or bridging therapy among patients with cardiogenic shock requiring ECMO 42-56 Moreover VA-ECMO use is associated with complications including bleeding renal failure Thus the benefits of this potentially life-saving support is still subject to discussion especially for VA-ECMO use in the setting of cardiogenic shock as the evidence is scarce Therefore it important to identify the patients related factors that may be associated with poor outcomes using real-world data We will conduct a retrospective observational study of all patients at Heart Hospital who required VA-ECMO support due to cardiogenic shock during 1062016 and 1062022 with the aim of quantifying the incidence of in-hospital mortality among patients who required VA-ECMO in the setting of cardiogenic shock along with determining the predictors of mortality
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None